Supported by an educational grant from Jazz Pharmaceuticals
Despite the fact that narcolepsy is the best-studied and most understood of primary disorders of excessive daytime sleepiness, it remains widely underrecognized and underdiagnosed, or misdiagnosed. Making the diagnosis can be even more challenging in children due to the presence of medical, psychiatric, and other sleep-related comorbidities. The impact of narcolepsy can be profound, impacting both behavior and academic performance. Children with narcolepsy are frequently considered lazy or unmotivated, and fluctuating levels of attentiveness, motor overactivity, or distractibility may lead to a misdiagnosis of attention deficit/hyperactivity disorder (ADHD). This Case Clinic illustrates optimal approaches to management in a 15-year-old male with increasing bouts of daytime sleepiness.
Psychiatrists, neurologists, pulmonologists, sleep specialists, and other clinicians who provide care to patients with narcolepsy
At the conclusion of this activity, participants should be better able to:
Identify the 5 core symptoms of narcolepsy and recognize them in patient presentations
Distinguish narcolepsy from other disorders with similar or overlapping signs and symptoms
Apply contemporary diagnostic criteria and assessment protocols for narcolepsy to improve the accuracy and timeliness of diagnosis
Implement and monitor the impact of individualized narcolepsy treatment plans
Conflict Of Interest Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.
Michael J. Thorpy, MD Professor of Clinical Neurology Albert Einstein College of Medicine Director, Sleep-Wake Disorders Center Montefiore Medical Center Bronx, NY
Dr. Thorpy has been a consultant for Jazz Pharmaceuticals, Merck, and Teva Pharmaceuticals. He has also served on a speakers’ bureau for Merck and has conducted research funded by Jazz Pharmaceuticals and Flamel Technologies.
Richard K. Bogan, MD, FCCP, FAASM Associate Clinical Professor University of South Carolina School of Medicine Chief Medical Officer SleepMed Inc. Columbia, SC
Dr. Bogan has been a consultant for Jazz Pharmaceuticals, Vanda, and XenoPort and has served on speakers’ bureaus for Jazz Pharmaceuticals and Merck. He has also conducted research funded by ApniCure, Balance, Eisai, Fresca Medical Inc, GSK, Jazz Pharmaceuticals, Merck, Novo Nordisk, Phillips, ResMed, Sensory Medical, Vanda, and XenoPort.
Accredited Provider Disclosure
Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Haymarket Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Jazz Pharmaceuticals or Haymarket Medical Education. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.